<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28610823</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>31</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Pre-vaccination evolution of antibodies among infants 0, 3 and 6months of age: A longitudinal analysis of measles, enterovirus 71 and coxsackievirus 16.</ArticleTitle><Pagination><StartPage>3817</StartPage><EndPage>3822</EndPage><MedlinePgn>3817-3822</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2017.06.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(17)30767-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Due to waning levels of maternal antibodies (measles; enterovirus 71, EV71; and coxsackievirus A16, CoxA16), some infants may lose protection against infection prior to vaccination. Using a longitudinal design, we examine how maternal antibody levels evolve over time in infants prior to vaccination.</AbstractText><AbstractText Label="METHODS">In 2013-2014, we collected sera at ages 0, 3 and 6months from infants. We assayed for levels of measles IgG antibody (717, 233 and 75 sample sera tested at months 0, 3 and 6, respectively), and neutralizing antibodies for EV71 and CoxA16 (225, 217, and 72). Demographic and health information were collected, and a linear mixed model (LMM) was used to describe antibody levels over time.</AbstractText><AbstractText Label="RESULTS">Pre-vaccination monotonic antibody decreases were observed for measles (1410, 195 and 22mIU/ml, p&lt;0.001), EV71 (1:19.9, 6.3 and 4.5, p&lt;0.001) and CoxA16 (1:16.3, 5.9, and 4.5, p&lt;0.001). At 6months of age, only 2.7% (95%CI, 0.6-8.3), 6.8% (95%CI, 2.7-14.4) and 5.6% (95%CI, 1.9-12.7) of infants were antibody positive for measles, EV71 and CoxA16, respectively. LMM findings indicated that infants with higher antibody titers at birth experienced a greater loss of antibody level. An infection rate of 1.3% (95%CI, 0.1-6.1) was reported for both EV71 and CoxA16.</AbstractText><AbstractText Label="CONCLUSIONS">Further modifications of vaccination strategies for measles, earlier vaccination for EV71 infection, and deployment of a CoxA16 vaccine need to be considered to limit infection among the very young.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Chuanxi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Zhejiang Chinese Medical University, Hangzhou, China; Guangzhou Center for Disease Control and Prevention, Guangzhou, China. Electronic address: fuchuanxi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Jichuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangzhou Center for Disease Control and Prevention, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Liwan District Maternal and Child Health Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yajing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sinovac Biotech Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yimin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangzhou Center for Disease Control and Prevention, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Guangzhou Center for Disease Control and Prevention, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>Sen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhicong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangzhou Center for Disease Control and Prevention, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: louisguoqing@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaman</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 GM110748</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007112" MajorTopicYN="Y">Immunity, Maternally-Acquired</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008459" MajorTopicYN="N">Measles virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus 16</Keyword><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Infants</Keyword><Keyword MajorTopicYN="N">Maternal antibodies</Keyword><Keyword MajorTopicYN="N">Measles</Keyword></KeywordList><CoiStatement><b>Competing interests</b>. JS discloses partial ownership of SK Analytics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28610823</ArticleId><ArticleId IdType="mid">NIHMS956885</ArticleId><ArticleId IdType="pmc">PMC5910062</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2017.06.002</ArticleId><ArticleId IdType="pii">S0264-410X(17)30767-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med. 2001;345:1331&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollema L, Smits GP, Berbers GA, Van Der Klis FR, Van Binnendijk RS, De Melker HE, et al. High risk of a large measles outbreak despite 30 years of measles vaccination in The Netherlands. Epidemiol Infect. 2014;142:1100&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9151141</ArticleId><ArticleId IdType="pubmed">23915981</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine. 2007;25:6296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">17629601</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan R, Slater PE, Duvdevani P, Golubev N, Mendelson E. Decay of maternally derived measles antibody in a highly vaccinated population in southern Israel. Pediatr Infect Dis J. 1995;14:965&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8584363</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ. 2010;340:c1626.</Citation><ArticleIdList><ArticleId IdType="pubmed">20483946</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing WJ, Liao QH, Viboud C, Zhang J, Sun JL, Wu JT, et al. Hand, foot, and mouth disease in China, 2008&#x2013;12: an epidemiological study. Lancet Infect Dis. 2014;14:308&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lixia W, Guang Z, Lee LA, Zhiwei Y, Jingjin Y, Jun Z, et al. Progress in accelerated measles control in the People&#x2019;s Republic of China, 1991&#x2013;2000. J Infect Dis. 2003;187(Suppl 1):S252&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12721922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Hao L, Zhang Y, Su Q, Rodewald L, An Z, et al. Monitoring progress towards the elimination of measles in China: an analysis of measles surveillance data. Bull World Health Organ. 2014;92:340&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007128</ArticleId><ArticleId IdType="pubmed">24839323</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu CX, Xu JX, Liu WB, Zhang W, Wang M, Nie J, et al. Low measles seropositivity rate among children and young adults: A sero-epidemiological study in southern China in 2008. Vaccine. 2010;28:8219&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">20688039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennon JL, Black FL. Maternally derived measles immunity in era of vaccine-protected mothers. J Pediatr. 1986;108:671&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">3701511</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui LW, Marusyk RG, Pabst HF. Measles virus specific antibody in infants in a highly vaccinated society. J Med Virol. 1991;33:199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">1880496</ArticleId></ArticleIdList></Reference><Reference><Citation>Pabst HF, Spady DW, Marusyk RG, Carson MM, Chui LW, Joffres MR, et al. Reduced measles immunity in infants in a well-vaccinated population. Pediatr Infect Dis J. 1992;11:525&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1528642</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics. 2007;120:e244&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, Lin KH, et al. Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol. 2009;47:3653&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Exp Rev Vaccines. 2016;15:803&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206811</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, et al. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Exp Rev Vaccines. 2016;15:129&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">26460695</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo ST, Chiang PS, Chao AS, Liou GY, Lin RY, Lin TY, et al. Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis. 2009;15:581&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671432</ArticleId><ArticleId IdType="pubmed">19331737</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Lu L, Chen M, Huang F, Zeng Y, Li XM, et al. Analysis of measles immunity level in persistent populations in Beijing, 2012. Zhonghua Yu Fang Yi Xue Za Zhi. 2013;47:916&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24378131</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu GZ, Ma R, Xu HJ, Ma YH, Dong HJ, Li Y, et al. Levels of transition on maternal transferred measles antibody in infants in 3 cities in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29:1074&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19173926</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Shirayama Y, Zhang Y, Ba W, Ikeda N, Mori R, et al. Duration of maternally derived antibody against measles: a seroepidemiological study of infants aged under 8 months in Qinghai, China. Vaccine. 2012;30:752&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22133513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, et al. Retrospective Study of the Incidence of HFMD and Seroepidemiology of Antibodies against EV71 and CoxA16 in Prenatal Women and Their Infants. Plos One. 2012:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3360679</ArticleId><ArticleId IdType="pubmed">22662137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Li F, Zheng X, Zhang H, Duan M, Yang Y, et al. Measles vaccine coverage estimates in an outbreak three years after the nation-wide campaign in China: implications for measles elimination, 2013. BMC Infect Dis. 2015;15:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4307911</ArticleId><ArticleId IdType="pubmed">25608672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao NY, Zhu Z, Jiang XH. Comparison and evaluation of enzyme-linked immunization assay kits with plague reduction neutralization test for detection of measles IgG antibody. Zhongguo Yi Miao He Mian Yi. 2009;15:215&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20084884</ArticleId></ArticleIdList></Reference><Reference><Citation>China Minister of Health. National guideline for Hand-foot-mouth disease diagnose and treatment. 2010.</Citation></Reference><Reference><Citation>West BT. Analyzing longitudinal data with the linear mixed models procedure in SPSS. Eval Health Prof. 2009;32:207&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">19679634</ArticleId></ArticleIdList></Reference><Reference><Citation>Han K, Chen S, Tang C, Wen J, Li J, Ni J, et al. The epidemiological and serological characteristics of measles in Dongguan, China, 2005&#x2013;2014. Hum Vaccin Immunother. 2016:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4994735</ArticleId><ArticleId IdType="pubmed">27003239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Boulton ML, Montgomery JP, Carlson B, Zhang Y, Gillespie B, et al. The epidemiology of measles in Tianjin, China, 2005&#x2013;2014. Vaccine. 2015;33:6186&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644448</ArticleId><ArticleId IdType="pubmed">26469719</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagneur A, Pinquier D, Aubert M, Balu L, Brissaud O, De Pontual L, et al. Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006. Clin Vaccine Immunol. 2008;15:1845&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593172</ArticleId><ArticleId IdType="pubmed">18815232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartter HK, Oyedele OI, Dietz K, Kreis S, Hoffman JP, Muller CP. Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatr Infect Dis J. 2000;19:635&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">10917222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar ML, Johnson CE, Chui LW, Whitwell JK, Staehle B, Nalin D. Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers. Vaccine. 1998;16:2047&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796063</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres VM, Strebel PM, Sutter RW. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis. 2000;31:110&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10913406</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J, Hsiao VY, et al. Hand, foot, and mouth disease in China: modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med. 2016;13:e1001958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755668</ArticleId><ArticleId IdType="pubmed">26882540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright HT, Jr, Landing BH, Lennette EH, Mc AR. Fatal infection in an infant associated with Coxsackie virus group A, type 16. N Engl J Med. 1963;268:1041&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">14001956</ArticleId></ArticleIdList></Reference><Reference><Citation>Legay F, Leveque N, Gacouin A, Tattevin P, Bouet J, Thomas R, et al. Fatal coxsackievirus A-16 pneumonitis in adult. Emerg Infect Dis. 2007;13:1084&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878248</ArticleId><ArticleId IdType="pubmed">18214187</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto K, Sanefuji M, Kusuhara K, Nishimura Y, Shimizu H, Kira R, et al. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis. 2009;15:1689&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866411</ArticleId><ArticleId IdType="pubmed">19861078</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Liu CF, Yan L, Li JJ, Wang LJ, Qi Y, et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J. 2012;9:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268717</ArticleId><ArticleId IdType="pubmed">22230340</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Zhu YF, Qi X, Zhang YJ, Li L, Deng F, et al. Analysis on the epidemiological and genetic characteristics of enterovirus type 71 and Coxsackie A16 virus infection in Jiangsu, China. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30:339&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19731523</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CC, Lau SK, Zhou B, Zhang MX, Tsoi HW, Chan KH, et al. Emergence of enterovirus 71 &#x201c;double-recombinant&#x201d; strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol. 2010;155:1413&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087135</ArticleId><ArticleId IdType="pubmed">20549263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014;10:360&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Guangzhou Beurea of Statistics. 2016  http://www.gzstats.gov.cn/tjdt/201607/t20160704_24446.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>